Latest Asx News

Nova Eye Medical has reported a record A$29.3 million in FY25 revenue, driven by sustained US growth and operational improvements, setting the stage for breakeven EBITDA in the first half of FY26.

Infragreen Group Limited has reported a robust FY25 performance, with pro forma revenue and EBITDA significantly exceeding forecasts, supported by a successful $40 million IPO.

Infragreen Group Limited reported a robust 190% increase in revenue for FY25 following its successful IPO, despite a significant statutory net loss. The company’s strategic acquisitions and expanded ownership stakes underpin a promising outlook in sustainable infrastructure.

SIV Capital Limited reported a statutory loss of $112,789 for the year ended June 2025, continuing its operational scale-down with only four active rental contracts. The company remains debt-free with $8.18 million in cash but its ASX securities remain suspended as it evaluates a confidential corporate opportunity.

James Hardie Industries confirms its Q1 FY26 earnings met market expectations despite a challenging North American housing market, while revising its FY26 guidance following the AZEK acquisition.

OM Holdings has terminated a previous sale agreement for its 90% stake in OM Materials (Qinzhou) due to buyer issues and entered a new deal to sell 60% to Shaanxi Sinian Metal & Mining, aiming to bolster working capital.

Global Health Limited reports solid progress towards profitability in FY2025, driven by a 6% increase in subscription revenue and strategic AI integration across its healthcare platforms.

Electro Optic Systems (EOS) has secured a role in the Australian Defence Force’s $1.3 billion Project LAND 156, aiming to develop advanced counter-drone capabilities over the next decade. Initial orders for EOS’s Slinger remote weapon system could boost revenues from 2026 onwards.

Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.

N1 Holdings reported a 6.8% revenue increase to $19.69 million for FY25, while net profit fell 21.1% to $855,826. The company advanced AI initiatives and expanded lending capacity, signaling strategic growth despite profit pressures.

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.

H&G High Conviction Limited reported a $2.9 million net loss for FY2025 amid challenging market conditions and completed a major asset sale to Hancock & Gore Limited, marking a pivotal shift in its business model.